Endocrine Abstracts

Background: Women with epilepsy may be at risk of developing PCOS, but it is unclear whether this is due to the disease or sodium valproate (VPA) therapy. We sought to determine androgenic status and cardiometabolic risk in women taking VPA monotherapy and compared these with subjects taking lamotrigine and healthy controls.Methods: Patients with epilepsy (age 18–43) with no known vascular risk were divided into 3 groups: VPA monotherapy (n=1...